10-K: Upexi Inc. Reports Fiscal Year 2024 Results, Navigates Strategic Shift

Upexi Inc.'s fiscal year 2024 saw a significant revenue decrease and a strategic shift towards branded product sales, alongside divestitures and operational consolidations.

Summary

• Upexi Inc. reported a 29% decrease in revenue for the fiscal year ended June 30, 2024, totaling $26 million, compared to $36.4 million in the previous year.
• Product sales declined by approximately $15.4 million, or 42%, primarily due to decreased sales through third-party channels like Amazon, while manufacturing sales partially offset this with approximately $5 million.
• The company's gross profit decreased by 39% to $12.8 million, and gross margin declined to 49.32% from 57.68%, largely due to a $3 million inventory write-off.
• Operating expenses decreased by 32% to $4.8 million, primarily due to a reduction in non-cash expenses such as stock compensation amortization.
• The company experienced a net loss of $23.6 million, compared to a net loss of $16.9 million in the prior year, with the increase primarily due to the above-mentioned changes.
• Upexi divested several subsidiaries, including VitaMedica and E-Core Technology, and consolidated its manufacturing operations to Florida.
• The company recognized a $7.8 million impairment of intangible assets and goodwill, primarily related to the Cygnet acquisition and the exit from the recommerce business.
• Upexi also recognized a $289,969 lease impairment on the Delray Beach warehouse and a $6.1 million valuation allowance on its deferred tax asset.
• The company had a net decrease in cash of $3.8 million, ending the year with $661,415 in cash on hand.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture with significant revenue decline, increased losses, and operational issues. While there are some positive strategic shifts, the overall sentiment is negative due to the poor financial performance and ongoing risks.

Positives

• The company has consolidated its manufacturing operations to Florida, which is expected to reduce costs.
• Upexi has shifted its focus to branded product sales, which management believes will improve profitability.
• The company has reduced its operating expenses by 32%, primarily through non-cash expense reductions.
• The sale of the Clearwater warehouse provided $1.37 million of working capital.
• The sale of VitaMedica provided $2.1 million in cash and reduced liabilities by $1.9 million.

Negatives

• Upexi experienced a significant 29% decrease in revenue year-over-year.
• The company's gross profit and gross margin declined substantially due to inventory write-offs.
• The net loss increased to $23.6 million, compared to $16.9 million in the prior year.
• The company recorded a $7.8 million impairment of intangible assets and goodwill.
• Upexi's cash balance decreased by $3.8 million, ending the year with $661,415.

Risks

• The company's limited operating history makes it difficult to evaluate business prospects.
• Upexi faces intense competition in its product markets.
• The company's success depends on its ability to protect its intellectual property rights.
• Cybersecurity breaches could disrupt business operations and compromise data.
• The company may not be able to effectively manage growth.
• The company is subject to evolving regulations in the CBD industry.
• The company has limited supply sources, and price increases or shortages of raw materials could harm the business.
• The company faces substantial risk of product liability claims and potential adverse product publicity.
• The company's independent distributors may fail to comply with applicable advertising laws and regulations.
• The company's failure to meet the continuing listing requirements of the NASDAQ Capital Market could result in a de-listing of its securities.

Future Outlook

The company expects its direct-to-consumer business to be the primary growth driver for the next several years, with additional brands and products. Management intends to finance operating costs over the next twelve months with existing cash on hand, cash flow from operations, proceeds from the sale of VitaMedica not yet received and additional short term debt financings, if necessary.

Management Comments

• Management has augmented the overall strategy of the Company to focus on product sales, including the development, production and distribution of branded products.
• Management expects the gross margin to improve with the change in strategic focus and the completed consolidation of operations.
• Management has implemented a strategy to change promotions, increase shipping prices and adjust packaging for whole sales verses direct to consumer shipments to lower the overall percentage of distribution costs to sales.
• Management expects that general and administrative expenses will decline for the period July 1, 2024 to September 30, 2024, with the most significant declines being realized in periods ending after December 31, 2024.

Industry Context

The company operates in a highly competitive market for consumer products, including health and wellness items, and faces challenges from both established players and new entrants. The company is also subject to evolving regulations in the CBD industry, which could impact its operations.

Comparison to Industry Standards

• The company's revenue decline of 29% is significant and indicates a challenging year compared to industry averages, which have seen growth in e-commerce and consumer product sales.
• The gross margin decline to 49.32% is below the average for consumer product companies, which typically aim for margins above 50%.
• The company's net loss of $23.6 million is substantial and highlights the need for improved operational efficiency and cost management.
• The divestiture of subsidiaries and consolidation of operations are strategic moves that are common in companies undergoing restructuring, but the success of these moves will depend on future execution.
• The company's reliance on Amazon as a sales channel is a common strategy, but the decline in sales through this channel indicates a need for diversification.
• The company's focus on branded products is a positive step, as it allows for better control over pricing and margins, similar to other successful consumer product companies.
• The company's financial results are worse than those of comparable companies in the consumer product and e-commerce sectors, which have generally seen growth in recent years.

Legal Proceedings

• Umpqua Bank has filed a lawsuit against Cygnet Online, LLC, and Eric Hanig, alleging default on a promissory note and business loan agreement, with a claim of $3,835,975.17 due.
• Get Fit Fast Supplements, LLC has filed an arbitration claim against Cygnet Online, LLC, and Eric Hanig, alleging failure to pay the full purchase price of an Asset Purchase Agreement, with a claim of $3,075,859.17 in damages.

Related Party Transactions

• The company entered into a lease agreement with MFA 2510 Merchant LLC, owned by CEO Allan Marshall.
• Allan Marshall, the CEO, was a minority buyer in the sale of VitaMedica.
• The company has a promissory note with Allan Marshall, the CEO, with a principal outstanding of $500,000.

Stakeholder Impact

• Shareholders have experienced a significant decrease in the value of their investment due to the company's poor financial performance.
• Employees may be affected by the company's restructuring and cost-cutting measures.
• Customers may experience changes in product availability and pricing due to the company's strategic shift.
• Suppliers may be impacted by the company's consolidation of operations and changes in purchasing patterns.
• Creditors may be concerned about the company's ability to repay its debts due to its financial losses.

Next Steps

• The company will focus on expanding its branded product portfolio through organic growth and supply chain optimization.
• The company will continue to expand its direct-to-consumer business.
• The company will focus on talent acquisition to strengthen its team of experts.
• The company will continue to monitor and evaluate the effectiveness of its internal controls and procedures and its internal controls over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

Key Dates

Keywords

Upexi, consumer products, e-commerce, manufacturing, distribution, brand owner, CBD, hemp, financial results, divestiture, acquisition, supply chain, Amazon, direct-to-consumer